Comparison of acid inhibition attained by esomeprazole and vonoprazan with reference to CYP2C19 genotypes
Not Applicable
- Conditions
- H. pylori infection and gastro-esophageal reflux desease
- Registration Number
- JPRN-UMIN000019890
- Lead Sponsor
- First Department of Medicine and Center for Clinical Research, Hamamatsu University School of Medicine, Hamamatsu, Japan
- Brief Summary
T. Kagami et al. Aliment Pharmacol Ther. 2016 May; 43 (10): 1048-59
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
Exclusion criteria are any underlying disease, smoking habit, past or present H. pylori infection, and habitual use of any medicine.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The primary outcome is acid inhibition with the four regimens as assessed by 24-hour intragastric pH monitoring on Day7 in each regimen.
- Secondary Outcome Measures
Name Time Method The secondary outcomes is serum gastrin level on Day 7 with each regimen as a surrogate marker of acid inhibition.